268 related articles for article (PubMed ID: 26453583)
61. New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome.
Teachey DT
Curr Opin Pediatr; 2012 Feb; 24(1):1-8. PubMed ID: 22157362
[TBL] [Abstract][Full Text] [Related]
62. Transgenic expression of the viral FLIP MC159 causes lpr/gld-like lymphoproliferation and autoimmunity.
Woelfel M; Bixby J; Brehm MA; Chan FK
J Immunol; 2006 Sep; 177(6):3814-20. PubMed ID: 16951343
[TBL] [Abstract][Full Text] [Related]
63. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
Papp KA; Menter MA; Abe M; Elewski B; Feldman SR; Gottlieb AB; Langley R; Luger T; Thaci D; Buonanno M; Gupta P; Proulx J; Lan S; Wolk R;
Br J Dermatol; 2015 Oct; 173(4):949-61. PubMed ID: 26149717
[TBL] [Abstract][Full Text] [Related]
64. Novel insights into FAS defects underlying autoimmune lymphoproliferative syndrome revealed by studies in consanguineous patients.
Ben-Mustapha I; Agrebi N; Barbouche MR
J Leukoc Biol; 2018 Mar; 103(3):501-508. PubMed ID: 29345341
[TBL] [Abstract][Full Text] [Related]
65. Immunologic evaluation and genetic defects of apoptosis in patients with autoimmune lymphoproliferative syndrome (ALPS).
Casamayor-Polo L; López-Nevado M; Paz-Artal E; Anel A; Rieux-Laucat F; Allende LM
Crit Rev Clin Lab Sci; 2021 Jun; 58(4):253-274. PubMed ID: 33356695
[TBL] [Abstract][Full Text] [Related]
66. Deletion of receptor for advanced glycation end products exacerbates lymphoproliferative syndrome and lupus nephritis in B6-MRL Fas lpr/j mice.
Goury A; Meghraoui-Kheddar A; Belmokhtar K; Vuiblet V; Ortillon J; Jaisson S; Devy J; Le Naour R; Tabary T; Cohen JH; Schmidt AM; Rieu P; Touré F
J Immunol; 2015 Apr; 194(8):3612-22. PubMed ID: 25762779
[TBL] [Abstract][Full Text] [Related]
67. P2X7 purinergic receptor plays a critical role in maintaining T-cell homeostasis and preventing lupus pathogenesis.
Mellouk A; Hutteau-Hamel T; Legrand J; Safya H; Benbijja M; Mercier-Nomé F; Benihoud K; Kanellopoulos JM; Bobé P
Front Immunol; 2022; 13():957008. PubMed ID: 36248812
[TBL] [Abstract][Full Text] [Related]
68. The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions.
Rieux-Laucat F; Magérus-Chatinet A; Neven B
J Clin Immunol; 2018 Jul; 38(5):558-568. PubMed ID: 29911256
[TBL] [Abstract][Full Text] [Related]
69. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.
Asahina A; Etoh T; Igarashi A; Imafuku S; Saeki H; Shibasaki Y; Tomochika Y; Toyoizumi S; Nagaoka M; Ohtsuki M;
J Dermatol; 2016 Aug; 43(8):869-80. PubMed ID: 26875540
[TBL] [Abstract][Full Text] [Related]
70. Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Weinhold KJ; Bukowski JF; Brennan TV; Noveck RJ; Staats JS; Lin L; Stempora L; Hammond C; Wouters A; Mojcik CF; Cheng J; Collinge M; Jesson MI; Hazra A; Biswas P; Lan S; Clark JD; Hodge JA
Clin Immunol; 2018 Jun; 191():10-20. PubMed ID: 29518577
[TBL] [Abstract][Full Text] [Related]
71. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).
Ghoreschi K; Jesson MI; Li X; Lee JL; Ghosh S; Alsup JW; Warner JD; Tanaka M; Steward-Tharp SM; Gadina M; Thomas CJ; Minnerly JC; Storer CE; LaBranche TP; Radi ZA; Dowty ME; Head RD; Meyer DM; Kishore N; O'Shea JJ
J Immunol; 2011 Apr; 186(7):4234-43. PubMed ID: 21383241
[TBL] [Abstract][Full Text] [Related]
72. Disturbed B-lymphocyte selection in autoimmune lymphoproliferative syndrome.
Janda A; Schwarz K; van der Burg M; Vach W; Ijspeert H; Lorenz MR; Elgizouli M; Pieper K; Fisch P; Hagel J; Lorenzetti R; Seidl M; Roesler J; Hauck F; Traggiai E; Speckmann C; Rensing-Ehl A; Ehl S; Eibel H; Rizzi M
Blood; 2016 May; 127(18):2193-202. PubMed ID: 26907631
[TBL] [Abstract][Full Text] [Related]
73. Characteristic T helper 2 T cell cytokine abnormalities in autoimmune lymphoproliferative syndrome, a syndrome marked by defective apoptosis and humoral autoimmunity.
Fuss IJ; Strober W; Dale JK; Fritz S; Pearlstein GR; Puck JM; Lenardo MJ; Straus SE
J Immunol; 1997 Feb; 158(4):1912-8. PubMed ID: 9029133
[TBL] [Abstract][Full Text] [Related]
74. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS
N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207
[TBL] [Abstract][Full Text] [Related]
75. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis.
Bettinardi A; Brugnoni D; Quiròs-Roldan E; Malagoli A; La Grutta S; Correra A; Notarangelo LD
Blood; 1997 Feb; 89(3):902-9. PubMed ID: 9028321
[TBL] [Abstract][Full Text] [Related]
76. The immune regulatory function of lymphoproliferative double negative T cells in vitro and in vivo.
Ford MS; Young KJ; Zhang Z; Ohashi PS; Zhang L
J Exp Med; 2002 Jul; 196(2):261-7. PubMed ID: 12119351
[TBL] [Abstract][Full Text] [Related]
77. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS).
Teachey DT; Obzut DA; Axsom K; Choi JK; Goldsmith KC; Hall J; Hulitt J; Manno CS; Maris JM; Rhodin N; Sullivan KE; Brown VI; Grupp SA
Blood; 2006 Sep; 108(6):1965-71. PubMed ID: 16757690
[TBL] [Abstract][Full Text] [Related]
78. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.
Panés J; Sandborn WJ; Schreiber S; Sands BE; Vermeire S; D'Haens G; Panaccione R; Higgins PDR; Colombel JF; Feagan BG; Chan G; Moscariello M; Wang W; Niezychowski W; Marren A; Healey P; Maller E
Gut; 2017 Jun; 66(6):1049-1059. PubMed ID: 28209624
[TBL] [Abstract][Full Text] [Related]
79. Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients.
Serdaroğlu S; Engin B; Çelik U; Erkan E; Aşkın Ö; Oba Ç; Kutlubay Z
Dermatol Ther; 2019 May; 32(3):e12844. PubMed ID: 30693634
[No Abstract] [Full Text] [Related]
80. FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function.
Magerus-Chatinet A; Stolzenberg MC; Loffredo MS; Neven B; Schaffner C; Ducrot N; Arkwright PD; Bader-Meunier B; Barbot J; Blanche S; Casanova JL; Debré M; Ferster A; Fieschi C; Florkin B; Galambrun C; Hermine O; Lambotte O; Solary E; Thomas C; Le Deist F; Picard C; Fischer A; Rieux-Laucat F
Blood; 2009 Mar; 113(13):3027-30. PubMed ID: 19176318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
